SMi Group is thrilled to present the 7th annual conference, Biosimilars Europe, taking place on 29th and 30th September 2016 in Central London, UK. Gathering an audience of principle scientists and regulatory experts involved in biotechnology and compliance, Biosimilars Europe 2016 will provide a perfect platform to discuss global market developments and strategies to market access.
Created with a top panel of industry thought leaders, this year's event will capture expert insight by honing in on the biosimilar product life-cycle from early stage developments, protein characterisation, and pricing and reimbursement; through to emerging markets and global developments.
Join us this autumn to arm yourself with the key requirements and tools for successful market entry through strategic direction on commercialisation; insight into potential therapeutic areas; and guidance on product quality assessment (PQA) in biosimilar development.
OUR NOTABLE SPEAKER LINE-UP WILL INCLUDE:
Huiguo Hu, General Manager of International Business, Shanghai CP Guojian Pharmaceutical Co Ltd
Dr Niraj Chhaya, Risk Management, Boehringer Ingelheim GmbH
Atanas Dimitrov, Head of Strategy and Portfolio Management, Merck Group
Dr Alok Sharma, Head, Bio-Analytical Development, Lupin Ltd
Dr Andrea Laslop, Head of Scientific Office, Austrian Agency for Health and Food Safety
Joan O'Callaghan, Research Scientist for Regulatory Science Ireland, Health Products Regulatory Authority, Ireland
WHY YOU NEED TO BE THERE IN 2016:
Hear how the evolving regulatory landscape and guidelines will impact on biosimilars
Overcome market access and commercialisation barriers
Assess market trends and align your business strategy on emerging markets
Technical updates on protein characterisation and analytical comparability to speed up data collection
PREVIOUS ATTENDEE TESTIMONIALS:
"Great discussions, networking and education"
"Impressive - beat my expectations"
Created with a top panel of industry thought leaders, this year's event will capture expert insight by honing in on the biosimilar product life-cycle from early stage developments, protein characterisation, and pricing and reimbursement; through to emerging markets and global developments.
Join us this autumn to arm yourself with the key requirements and tools for successful market entry through strategic direction on commercialisation; insight into potential therapeutic areas; and guidance on product quality assessment (PQA) in biosimilar development.
OUR NOTABLE SPEAKER LINE-UP WILL INCLUDE:
Huiguo Hu, General Manager of International Business, Shanghai CP Guojian Pharmaceutical Co Ltd
Dr Niraj Chhaya, Risk Management, Boehringer Ingelheim GmbH
Atanas Dimitrov, Head of Strategy and Portfolio Management, Merck Group
Dr Alok Sharma, Head, Bio-Analytical Development, Lupin Ltd
Dr Andrea Laslop, Head of Scientific Office, Austrian Agency for Health and Food Safety
Joan O'Callaghan, Research Scientist for Regulatory Science Ireland, Health Products Regulatory Authority, Ireland
WHY YOU NEED TO BE THERE IN 2016:
Hear how the evolving regulatory landscape and guidelines will impact on biosimilars
Overcome market access and commercialisation barriers
Assess market trends and align your business strategy on emerging markets
Technical updates on protein characterisation and analytical comparability to speed up data collection
PREVIOUS ATTENDEE TESTIMONIALS:
"Great discussions, networking and education"
"Impressive - beat my expectations"
